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Objective: To study the effect of immune formulation-assisted conventional therapy on
anti-infective ability of multidrug-resistant Mycobacterium tuberculosis infection mice.
Methods: BALB/c mice were used as experimental animals, multidrug-resistant M.
tuberculosis infection models were built, randomly divided into model group, moxi-
ﬂoxacin group, thymopentin group and combined treatment group and given corre-
sponding drug intervention, and then colony numbers in the spleen and lung, T
lymphocyte subset contents and programmed death-1 (PD-1) expression levels in pe-
ripheral blood were detected.
Results: Colony numbers in lung and spleen of moxiﬂoxacin group and thymopentin
group were signiﬁcantly lower than those of model group and colony numbers in lung
and spleen of combined treatment group were signiﬁcantly lower than those of moxi-
ﬂoxacin group and thymopentin group; contents of CD3+CD4+T cells, Th1 and Th17 in
peripheral blood of moxiﬂoxacin group and thymopentin group were higher than those of
model group, and contents of CD3+CD8+T cells, Th2 and Treg were lower than those of
model group; contents of CD3+CD4+T cells, Th1 and Th17 in peripheral blood of
combined treatment group were higher than those of moxiﬂoxacin group and thymo-
pentin group, and contents of CD3+CD8+T cells, Th2 and Treg were lower than those of
moxiﬂoxacin group and thymopentin group; PD-1 expression levels on T lymphocyte, B
lymphocyte and monocyte surface in peripheral blood of moxiﬂoxacin group and thy-
mopentin group were lower than those of model group, and PD-1 expression levels on T
lymphocyte, B lymphocyte and monocyte surface in peripheral blood of combined
treatment group were lower than those of moxiﬂoxacin group and thymopentin group.
Conclusions: Immune formulation thymopentin can enhance the anti-infective ability of
multidrug-resistant M. tuberculosis infection mice, decrease bacterial load in lung and
spleen, and enhance immune function.1. Introduction
Tuberculosis is a respiratory infectious disease caused by
Mycobacterium tuberculosis (M. tuberculosis), and affected by
bacterial mutation, wide use of chemotherapy drugs and otherfactors, the incidence of multidrug-resistant tuberculosis caused
by multidrug-resistant M. tuberculosis infection is rising [1,2].
The killing effect of conventional chemotherapy drugs on
multidrug-resistant M. tuberculosis is not ideal, and second-
line anti-tubercular drugs have longer course of treatment,
more adverse reactions and lower cure rate [3–5]. In recent years,
more and more studies have realized that weakened immune
function is associated with multidrug-resistant tuberculosis
infection, and targeted immune formulation adjuvant therapy has
become an important part of anti-tuberculosis comprehensive
treatment [6]. Thymopentin is a drug enhancing immune activity
and clinical common immune formulation [7]. In the followingess article under the CC BY-NC-ND license
Table 2
Comparison of T lymphocyte subset contents in peripheral blood.
n CD3+CD4+T cells CD3+CD8+T cells
Model group 12 37.35 ± 4.25 39.22 ± 5.19
Moxiﬂoxacin group 12 41.18 ± 5.29a 33.61 ± 3.88a
Thymopentin group 12 46.84 ± 5.51a 30.17 ± 3.22a
Combined treatment
group
12 57.31 ± 6.23abc 21.36 ± 3.21abc
a: compared with model group, there were differences, P < 0.05;
b: compared with moxiﬂoxacin group, there were differences, P < 0.05;
c: compared with thymopentin group, there were differences, P < 0.05.
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therapy on anti-infective ability of multidrug-resistant
M. tuberculosis infection mice was analyzed.
2. Materials and methods
2.1. Experimental materials
Experimental animals were 48 SPF level BALB/c mice
weighted (18–22) g, were randomly divided into model group,
moxiﬂoxacin group, thymopentin group and combined treatment
group, each group with 12 cases. Thymopentin was from Beijing
Double-Crane Pharmaceuticals Co., Ltd., moxiﬂoxacin was
from Bayer Healthcare Co., Ltd., and ﬂuorescent antibodies
were from Santa Cruz Company.
2.2. Model establishment and drug intervention methods
7H9 liquid medium containing 1 × 106/mL multidrug-
resistant M. tuberculosis was prepared, and multidrug-resistant
M. tuberculosis infection models of aerosol infection mice
were built and given drug intervention from the 21 d after
infection. Moxiﬂoxacin group received intragastric administra-
tion of 100 mg/kg moxiﬂoxacin, thymopentin group received
subcutaneous infection of 1 mg/kg thymopentin, combined
treatment group received intragastric administration of 100 mg/
kg moxiﬂoxacin and subcutaneous infection of 1 mg/kg thy-
mopentin, and model group received subcutaneous infection and
intragastric administration of same doses of saline.
2.3. Detection of colony numbers in visceral organs
Four weeks, eight weeks and sixteen weeks after treatment,
mice were killed and anatomized under sterile conditions to get
the lung and spleen, appropriate amount of tissue was cut off,
homogenized, diluted, then inoculated in 7H11 medium and
continuously cultured for 4 weeks, and then colony forming unit
was counted.
2.4. Detection of T lymphocyte subset contents in
peripheral blood
Sixteen weeks after treatment, mice were taken and killed by
decapitation to collect peripheral blood, ﬂuorescent antibodies of
CD3, CD4 and CD8 as well as IFN-g, IL-4, Th17 and CD25
were incubated respectively away from light, hemolysin was
added for 15 min of hemolysis, then DPBS 1000 mL was added
to re-suspend cells, contents of different T cell subsets were
detected in ﬂow cytometer, and at the time of detection, exci-
tation light was argon ion laser 488 nm.Table 1
Comparison of colony numbers in lung and spleen (lg colony forming unit).
n 4 weeks
Lung Spleen
Model group 12 6.22 ± 0.62 4.35 ± 0.49
Moxiﬂoxacin group 12 4.94 ± 0.53a 3.35 ± 0.35a
Thymopentin group 12 5.12 ± 0.59a 3.29 ± 0.31a
Combined treatment group 12 3.15 ± 0.39abc 2.21 ± 0.27abc
a: compared with model group, there were differences, P < 0.05; b: compared
with thymopentin group, there were differences, P < 0.05.2.5. Detection of PD-1 expression in lymphocytes in
peripheral blood
Sixteen weeks after treatment, mice were taken and killed by
decapitation to collect peripheral blood, ﬂuorescent antibodies of
CD3, CD19 and CD14 as well as programmed death-1 (PD-1)
were incubated away from light respectively, hemolysin was
added for 15 min of hemolysis, then DPBS 1000 mL was added
to re-suspend cells, contents of different T cell subsets were
detected in ﬂow cytometer, and at the time of detection, exci-
tation light was argon ion laser 488 nm.
2.6. Statistical process methods
SPSS19.0 software was used to input and process data,
comparison among groups was by variance analysis, pair wise
comparison was by LSD-t method, and P < 0.05 was the stan-
dard of statistical signiﬁcance in differences.
3. Results
3.1. Colony numbers in lung and spleen
Four weeks, eight weeks and sixteen weeks after treatment,
analysis of colony numbers in lung and spleen was as follows:
(1) variance analysis showed that colony numbers in lung and
spleen of four groups were different. (2) Pair wise comparison
showed that colony numbers in lung and spleen of moxiﬂoxacin
group and thymopentin group were signiﬁcantly lower than
those of model group and colony numbers in lung and spleen of
combined treatment group were signiﬁcantly lower than those of
moxiﬂoxacin group and thymopentin group (Table 1).
3.2. Contents of T lymphocyte subsets in peripheral
blood
Contents of CD3+CD4+T cells in peripheral blood of moxi-
ﬂoxacin group and thymopentin group were higher than that of8 weeks 16 weeks
Lung Spleen Lung Spleen
6.77 ± 0.82 5.19 ± 0.62 7.67 ± 0.83 5.76 ± 0.59
5.32 ± 0.62a 3.87 ± 0.46a 5.91 ± 0.61a 4.47 ± 0.65a
5.77 ± 0.49a 4.01 ± 0.48a 5.24 ± 0.68a 4.69 ± 0.50a
3.47 ± 0.42abc 2.85 ± 0.25abc 3.08 ± 0.19abc 2.32 ± 0.28abc
with moxiﬂoxacin group, there were differences, P < 0.05; c: compared
Table 3
Comparison of the contents of different CD4+T lymphocyte subsets in peripheral blood.
n Th1 Th2 Th17 Treg
Model group 12 5.82 ± 0.76 6.12 ± 0.87 0.87 ± 0.10 7.23 ± 0.88
Moxiﬂoxacin group 12 7.25 ± 0.83a 5.08 ± 0.38a 1.06 ± 0.10a 5.78 ± 0.84a
Thymopentin group 12 7.71 ± 0.95a 4.77 ± 0.49a 1.14 ± 0.18a 5.12 ± 0.73a
Combined treatment group 12 9.92 ± 1.05abc 2.89 ± 0.23abc 1.59 ± 0.19abc 3.29 ± 0.41abc
a: compared with model group, there were differences, P < 0.05; b: compared with moxiﬂoxacin group, there were differences, P < 0.05; c: compared
with thymopentin group, there were differences, P < 0.05.
Table 4
PD-1 expression levels in lymphocytes and monocytes in peripheral blood.






Model group 12 54.66 ± 6.24 44.44 ± 5.78 33.53 ± 4.23
Moxiﬂoxacin group 12 41.37 ± 5.28a 33.26 ± 4.12a 26.78 ± 2.95a
Thymopentin group 12 39.56 ± 5.47a 30.91 ± 3.79a 25.38 ± 3.17a
Combined treatment group 12 22.78 ± 3.92abc 19.32 ± 2.68abc 15.30 ± 1.72abc
a: compared with model group, there were differences, P < 0.05; b: compared with moxiﬂoxacin group, there were differences, P < 0.05; c: compared
with thymopentin group, there were differences, P < 0.05.
Xiu-Li Yuan et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(3): 293–297 295model group, and contents of CD3+CD8+T cells were lower than
that of model group; content of CD3+CD4+T cells in peripheral
blood of combined treatment group was higher than those of
moxiﬂoxacin group and thymopentin group, and content of
CD3+CD8+T cells was lower than those of moxiﬂoxacin group
and thymopentin group (Table 2).
3.3. Contents of different CD4+T lymphocyte subsets in
peripheral blood
Contents of Th1 and Th17 cells in peripheral blood of
moxiﬂoxacin group and thymopentin group were higher than
those of model group, and contents of Th2 and Treg cells were
lower than those of model group; contents of Th1 and Th17 cells
in peripheral blood of combined treatment group were higher
than those of moxiﬂoxacin group and thymopentin group, and
contents of Th2 and Treg cells were lower than those of moxi-
ﬂoxacin group and thymopentin group (Table 3).
3.4. PD-1 expression levels in lymphocytes and
monocytes in peripheral blood
PD-1 expression levels on T lymphocyte, B lymphocyte and
monocyte surface in peripheral blood of moxiﬂoxacin group and
thymopentin group were lower than those of model group, and
PD-1 expression levels on T lymphocyte, B lymphocyte and
monocyte surface in peripheral blood of combined treatment
group were lower than those of moxiﬂoxacin group and thy-
mopentin group (Table 4).
4. Discussion
Multidrug-resistant tuberculosis caused by multidrug-
resistant M. tuberculosis infection is the difﬁculty and
emphasis of clinical treatment. The main mechanism of M.
tuberculosis resistance is inhibiting body's cellular immune
response [8]. Related study conﬁrms that normal M. tuberculosis
H37Rv strain doesn't have inhibitory effect on the activation and
maturation of Th1 and Th2 cells, and after bacterial infection,the body can induce Th1 type immune response through
autoimmune response and kill M. tuberculosis [9]; multidrug-
resistant M. tuberculosis strains can inhibit the differentiation
and maturation of CD4+T lymphocytes, inhibit the maturation of
Th1 cells, promote the maturation of Th2 cells, and reduce the
generation of cytokines such as IL-2, TNF-a and IFN-g as well
as the killing effect of above cytokines onM. tuberculosis, and it
is difﬁcult for the body to kill M. tuberculosis through autoim-
mune mechanism [10,11]. Multidrug-resistant tuberculosis is
mostly insensitive to ﬁrst-line chemotherapy drugs, second-line
chemotherapy drugs are with higher price, more adverse re-
actions as well as longer drug administration time and course of
treatment, and the cure rate is not ideal [12,13].
Broad-spectrum antibacterial drug moxiﬂoxacin is the
essential drug of clinical treatment of multidrug-resistant
tuberculosis at present [14]. The drug has high afﬁnity to
quinolone resistance-determining area of DNA helicase A sub-
unit in multidrug-resistant strains, and it can infect bacteria DNA
replication and damage the structure of the bacteria [15,16].
However, the curative effect of moxiﬂoxacin alone is not very
ideal. Based on the inhibitory effect of multidrug-resistant M.
tuberculosis on immune function, more and more scholars
advocate use of immune formulation to treat multidrug-resistant
tuberculosis [17]. Thymopentin is a kind of bioactive peptide
extracted from newborn calf thymus tissue, and it has the
function of stimulating T lymphocyte differentiation,
maturation and proliferation as well as releasing a variety of
cytokines. Related clinical studies prove that thymopentin has
promoting effect on cellular immune function, which is
speciﬁcally manifested as regulating the contents and function
of T lymphocyte subsets [18,19].
In the research, based on routine moxiﬂoxacin anti-infection
treatment, immune formulation thymopentin was used for
adjuvant therapy, aiming to exert the regulating effect of thy-
mopentin on immune function. In order to clarify the effect of
immune formulation-assisted conventional therapy on anti-
infective ability of multidrug-resistant M. tuberculosis infec-
tion mice, colony numbers in lung and spleen of different
treatment groups were compared. After M. tuberculosis
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mechanism can kill pathogenic bacteria or inhibit the growth of
pathogenic bacteria, and reduce the number of colonies in the
visceral organs. Analysis of colony numbers in lung and spleen
showed that colony numbers in lung and spleen of moxiﬂoxacin
group and thymopentin group were signiﬁcantly lower than
those of model group and colony numbers in lung and spleen of
combined treatment group were signiﬁcantly lower than those of
moxiﬂoxacin group and thymopentin group. This indicated that
both moxiﬂoxacin and thymopentin had inhibitory effect on the
growth of multidrug-resistantM. tuberculosis, and combined use
of the two drugs had synergistic effect and enhanced the anti-
infective ability of multidrug-resistant M. tuberculosis infec-
tion mice together.
Cellular immunity is the main immune mechanism of the body
to kill M. tuberculosis, and T lymphocytes are the main cells to
execute cellular immune response [20]. T lymphocyte maturation
process experiences positive and negative selection, two types of
mature T cell that are generated include CD3+CD4+T cell and
CD3+CD8+T cell, the former is an important helper cell and the
latter is an important suppressor cell [21,22]. In the body's anti-
tuberculosis immune response, CD3+CD4+T cell content and
CD4+/CD8+ ratio increase, and CD3+CD8+T cell content de-
creases. In the research, the proportions of T lymphocyte subsets
in peripheral blood were compared and analyzed after thymo-
pentin treatment, and results showed that the contents of
CD3+CD4+T cells in peripheral blood of moxiﬂoxacin group and
thymopentin group were higher than that of model group, and
contents of CD3+CD8+T cells were lower than that of model
group; content of CD3+CD4+T cells in peripheral blood of
combined treatment group was higher than those of moxiﬂoxacin
group and thymopentin group, and content of CD3+CD8+T cells
was lower than those of moxiﬂoxacin group and thymopentin
group. It indicated that after moxiﬂoxacin and thymopentin
monotherapy, the immune function of multidrug-resistant M.
tuberculosis infection mice was enhanced, and the effect of
combined use of the two drugs on enhancing cellular immune
function of mice was more signiﬁcant.
In the process of exerting immune function, CD4+CD8-T
lymphocytes can be activated into different subsets that exert
different functions, speciﬁcally including Th1, Th2, Th17 and
Treg cells [23]. Th1 and Th2 is a pair of cells earliest discovered
in CD4+T cell subsets, and the former mainly secretes IL-2 and
IFN-g, and can induce cellular immune response and kill path-
ogenic microorganism; the latter mainly secretes IL-4 and IL-10,
and can induce B cells to generate antibodies and inhibit the
killing effect of macrophages on pathogenic microorganism to a
certain extent [24,25]. Th17 and Treg are newly discovered
members of CD4+T cell subsets, Th17 can secrete IL-17 and
exert pathogen-killing effect similar to that of cytokines such as
IL-2 and IFN-g; Treg can inhibit the activation of Th17 and the
generation of IL-17, and it has immunosuppressive effect [26,27].
In the research, further analysis of CD4+CD8-T lymphocyte
subset contents in peripheral blood of four groups showed that
both moxiﬂoxacin and thymopentin monotherapy could increase
Th1 and Th17 contents and decrease Th2 and Treg contents, and
the modulating effect of combined use of the two drugs on
cellular immune function was more signiﬁcant.
Studies about the body's anti-tuberculosis immune response
in recent years believe that PD-1 and its ligand PD-L1, as
negative costimulatory molecules, are involved in the regulation
of body's immune response and have negative regulatory effecton lymphocyte activation. There is PD-1 expression on T
lymphocyte, B lymphocyte and monocyte surface, PD-1 and its
ligand PD-L1 can input suppressor signal through immunor-
eceptor tyrosine-based inhibitory motif of cytoplasm end
sequence, and ﬁnally realize the inhibitory effect on immune
response. Multidrug-resistant M. tuberculosis infection can
activate PD-1 and inhibit body's immune response. In the
research, analysis of PD-1 expression levels on T lymphocyte, B
lymphocyte and monocyte surface showed that PD-1 expression
levels on T lymphocyte, B lymphocyte and monocyte surface in
peripheral blood of moxiﬂoxacin group and thymopentin group
were lower than those of model group, and PD-1 expression
levels on T lymphocyte, B lymphocyte and monocyte surface in
peripheral blood of combined treatment group were lower than
those of moxiﬂoxacin group and thymopentin group.
Based on above discussion, it can be concluded that immune
formulation thymopentin can enhance anti-infective ability of
multidrug-resistant M. tuberculosis infection mice, decrease
bacterial load in lung and spleen, and enhance immune function.
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